Systemic Lupus Erythematosus |
| Completed | 2b | 350 | Europe, Canada, Japan, US, RoW | Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg | Pfizer | Systemic Lupus Erythematosus | 10/23 | 10/23 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2b | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 05/24 | 05/25 | | |
NCT05967520: JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 2a | 48 | RoW | JMKX000189, Placebo | Jemincare | Lupus Erythematosus, Systemic | 05/25 | 12/25 | | |
| Active, not recruiting | 2 | 93 | Europe, Canada, Japan, US, RoW | belimumab 10mg/kg, placebo, Normal Saline | GlaxoSmithKline, Human Genome Sciences Inc., a GSK Company | Systemic Lupus Erythematosus | 01/18 | 04/28 | | |
2020-000473-25: ESKETamine for FIBromyalgia treatment Traitement de la fibromyalgie par S-Ketamine |
|
|
| Not yet recruiting | 2 | 210 | Europe | Vesierra, Solution for infusion, Vesierra | Grand Hôpital de Charleroi, Grand Hôpital de Charleroi | Patients diagnosed with a fibromyalgia syndrome as established by the 2016 ACR criteria and presenting criteria of central sensitization syndrome (based of the CSI (CSI>40))., Patients diagnosed with a fibromyalgia syndrome, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
2021-000962-14: A drug trial to evaluate the safety and efficacy of daratumumab, an agent already approved for other diseases, in combination with standard background anti-rheumatic therapy in patients with moderate-to-severe systemic lupus erythematosus Eine Medikamentenstudie zur Untersuchung der Sicherheit und Wirksamkeit des bereits für andere Erkrankungen zugelassenen Wirkstoffs Daratumumab in Kombination mit einer anti-rheumatischen Standard-Begleittherapie bei Patienten mit mittelschwerem bis schwerem systemischen Lupus erythematodes |
|
|
| Not yet recruiting | 2 | 10 | Europe | Daratumumab, JNJ-54767414, Solution for injection, Darzalex | Charité - Universitätsmedizin Berlin, JANSSEN-CILAG GmbH | Systemic Lupus Erythematosus Systemischer Lupus Erythematodes (SLE), Systemic Lupus Erythematosus Systemischer Lupus Erythematodes (SLE), Diseases [C] - Immune System Diseases [C20] | | | | |
2020-005569-14: A Clinical Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus |
|
|
| Ongoing | 2 | 225 | Europe | Nipocalimab, JNJ-80202135, Solution for infusion | Janssen-Cilag International NV, Janssen Research & Development, LLC | Active Systemic Lupus Erythematosus, Active Systemic Lupus Erythematosus, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000097-29: A Phase II Randomized Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis Estudio fase II, aleatorizado y controlado paraevaluar la eficacia, seguridad y farmacocinética de obinutuzumab en pacientes adolescentes con nefritis lúpica de casle III o IV activa |
|
|
| Not yet recruiting | 2 | 30 | Europe | Obinutuzumab, mycophenolate mofetil, RO5072759, Concentrate for solution for infusion, Tablet, Gazyvaro, Myfenax | Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., F. HOFFMANN - LA ROCHE LTD., F. Hoffman-La Roche Ltd. | Lupus Nephritis (LN) Nefritis lúpica (NL), Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). SLE is an autoimmune disease, in which the body’s immune system attacks its own healthy body tissue. La nefritis lúpica es una inflamación del riñón causada por el lupus eritematoso sistémico(LES).LES es una enfermedad autoinmune,en la que el sistema inmune del cuerpo ataca sus propios tejidos sanos, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-004021-25: A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) |
|
|
| Ongoing | 2 | 600 | Europe | TLR7/8 Antagonist (2.5mg), TLR7/8 Antagonist (10mg), BMS-986256, Capsule, hard | Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation | Active Systemic Lupus Erythematosus., SLE is a chronic autoimmune disease in which the immune system attacks its own tissues, causing inflammation and tissue damage in the affected organs (skin, joints, kidneys, heart and other organs)., Diseases [C] - Immune System Diseases [C20] | | | | |
| Recruiting | 2 | 146 | RoW | Sirolimus, rapamycin, Placebo | Chinese SLE Treatment And Research Group, Beijing Municipal Science & Technology Commission, North China Pharmaceutical Group Corporation | Systemic Lupus Erythematosus | 10/24 | 05/25 | | |
NCT04835883: Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients |
|
|
| Recruiting | 2 | 10 | RoW | CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) | Hanyang University Seoul Hospital, Corestem, Inc., Ministry of Health & Welfare, Korea | Systemic Lupus Erythematosus | 11/21 | 01/26 | | |
NCT03396393: Exploratory Study of DHA in Systemic Lupus Erythematosus Patients |
|
|
| Not yet recruiting | 2 | 120 | NA | Dihydroartemisinin tablet, No other names, Placebo tablet | Kunming Pharmaceuticals, Inc. | Systemic Lupus Erythematosus | 12/21 | 12/22 | | |
2021-001406-30: A study investigating the treatment of Systemic Lupus Erythematosus with LY3361237 |
|
|
| Not yet recruiting | 2 | 90 | Europe | LY3361237, Solution for injection | Eli Lilly and Company, Eli Lilly and Company | Systemic Lupus Erythematosus (SLE), Systemic Lupus Erythematosus, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-004648-27: A Study of Enpatoran in Patients With Systemic Lupus Erythematosus andCutaneous Lupus Erythematosus Un estudio de enpatoran en pacientes con lupus eritematoso sistémico y lupus eritematoso cutáneo |
|
|
| Not yet recruiting | 2 | 532 | Europe, RoW | Enpatoran 25mg, M5049, Film-coated tablet | Merck Healthcare KGaA, Merck Healthcare KGaA | Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) Lupus eritematoso sistémico (LES) y Lupus eritematoso cutáneo (LEC), Systemic lupus erythematosus (SLE) and cutaneous lupuserythematosus (CLE) Lupus eritematoso sistémico (LES) y Lupus eritematoso cutáneo (LEC), Diseases [C] - Immune System Diseases [C20] | | | | |
2021-001567-25: Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus Eficacia y seguridad de SAR441344 para el tratamiento del Lupus Eritematoso Sistémico. |
|
|
| Not yet recruiting | 2 | 166 | Europe | SAR441344, SAR441344, Solution for injection | Sanofi-Aventis Recherche et Développement, SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi-Aventis Recherche et Développement, Sanofi-aventis Recherche & Développement | Systemic lupus erythematosus Lupus Eritematoso Sistémico, Systemic lupus erythematosus Lupus Eritematoso Sistémico, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-002205-22: "Clinical research study to measure how good and how safe Branebrutinib compared to a placebo is in treating participants with Systemic Lupus Erythematosus or Primary Sjögren’s Syndrome, or participants with Rheumatoid Arthritis when being treated with Branebrutinib and methotrexate followed with Abatacept treatment." |
|
|
| Not yet recruiting | 2 | 185 | Europe | Branebrutinib, Abatacept, BMS-986195, BMS-188667, Capsule, hard, Solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe | Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Research and Development, Bristol-Myers Squibb Company | SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis, Lupus, Sjögren’s Syndrome and Arthritis are autoimmune diseases that develops when body's immune system overreacts to unknown stimulus making antibodies/proteins directed against own's body tissues., Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 2 | 291 | Europe, Canada, Japan, US, RoW | LY3471851, Rezpegaldesleukin, REZPEG, NKTR-358, Placebo | Nektar Therapeutics, Eli Lilly and Company | Systemic Lupus Erythematosus | 01/23 | 02/23 | | |
| Active, not recruiting | 2 | 25 | Europe, Japan, US, RoW | Belimumab | GlaxoSmithKline | Systemic Lupus Erythematosus | 01/23 | 04/27 | | |
DARALUP, NCT04810754: An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 2 | 10 | NA | Daratumumab Injection, DARZALEX (trade name) | Charite University, Berlin, Germany, Janssen-Cilag G.m.b.H, Labor Berlin-Charité Vivantes G.m.b.H, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Charité Clinical Trial Office (CTO) | Systemic Lupus Erythematosus | 03/23 | 12/23 | | |
| Completed | 2 | 214 | Europe, US, RoW | VIB7734, Daxdilimab, HZN-7734, Placebo | Amgen | Lupus Erythematosus, Systemic | 05/23 | 06/23 | | |
| Terminated | 2 | 168 | Europe, Canada, Japan, US, RoW | Efavaleukin Alfa, AMG 592, Placebo, Standard of Care | Amgen | Active Systemic Lupus Erythematosus | 05/23 | 05/23 | | |
| Completed | 2 | 244 | Europe, Canada, Japan, US, RoW | Rozibafusp Alfa, Placebo for Rozibafusp Alfa | Amgen | Systemic Lupus Erythematosus (SLE) | 07/23 | 07/23 | | |
|
2022-000855-35: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 2 | 156 | Europe | Daxdilimab, HZN-7734, VIB7734, Solution for injection | Horizon Therapeutics Ireland DAC, Horizon Therapeutics Ireland DAC | Systemic Lupus Erythematosus (SLE), Systemic Lupus Erythematosus, Diseases [C] - Immune System Diseases [C20] | | | | |
MEASURE, NCT03355482: MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE |
|
|
| Terminated | 2 | 9 | US | Methylprednisolone, Placebos | Oklahoma Medical Research Foundation, Bristol-Myers Squibb | Systemic Lupus Erythematosus Arthritis | 02/22 | 12/22 | | |
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders |
|
|
| Completed | 2 | 257 | US | Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent | National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc. | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS) | 06/23 | 03/24 | | |
| Recruiting | 2 | 270 | Europe, Canada, Japan, US, RoW | MK-6194, Placebo | Merck Sharp & Dohme LLC | Systemic Lupus Erythematosus | 01/26 | 07/27 | | |
NCT04451772 / 2020-001690-72: A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State |
|
|
| Completed | 2 | 185 | Europe, Japan, US, RoW | Elsubrutinib, ABBV-105, Placebo for Elsubrutinib, Upadacitinib, ABT-494, RINVOQ, Placebo for Upadacitinib | AbbVie | Systemic Lupus Erythematosus (SLE) | 01/24 | 01/24 | | |
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus |
|
|
| Completed | 2 | 85 | Europe, US, RoW | LY3361237, Placebo | Eli Lilly and Company | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
| Terminated | 2 | 155 | Europe, US, RoW | Daxdilimab, HZN-7734 | Amgen, Horizon Therapeutics Ireland DAC | Systemic Lupus Erythematosus | 10/23 | 10/23 | | |
NCT06293365: Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease |
|
|
| Not yet recruiting | 2 | 140 | NA | VAY736 1ml PFS, Ianalumab, VAY736 2 ml PFS, VAY736 2ml AI | Novartis Pharmaceuticals | Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis | 07/25 | 02/29 | | |
| Active, not recruiting | 2 | 532 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 07/24 | 08/24 | | |
| Active, not recruiting | 2 | 107 | Europe, Japan, RoW | VAY736, Ianalumab, VAY736 Placebo, Ianalumab/Placebo, CFZ533, Iscalimab, CFZ533 Placebo, Iscalimab/Placebo | Novartis Pharmaceuticals | Systemic Lupus Erythematosus (SLE) | 07/22 | 04/26 | | |
|
NCT05504187: Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 2 | 24 | NA | KP104 | Kira Pharmacenticals (US), LLC. | Systemic Lupus Erythematosus | 10/24 | 10/24 | | |
| Active, not recruiting | 2 | 130 | Europe, US, RoW | ALPN-101, Placebo | Alpine Immune Sciences, Inc. | Systemic Lupus Erythematosus | 11/24 | 01/25 | | |
| Recruiting | 2 | 116 | Europe, US, RoW | SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC | Sanofi | Systemic Lupus Erythematosus | 09/25 | 11/26 | | |
| Active, not recruiting | 2 | 228 | Europe, Japan, US, RoW | Placebo, Nipocalimab, JNJ-80202135, M281, Standard-of-care treatment | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Systemic Lupus Erythematosus | 05/24 | 12/24 | | |
| Active, not recruiting | 2 | 261 | Europe, Canada, Japan, US, RoW | BMS-986165, Deucravacitinib | Bristol-Myers Squibb | Systemic Lupus Erythematosus | 03/25 | 03/25 | | |
LUMUS, NCT05966480: Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 388 | Europe, US, RoW | ESK-001, Placebo | Alumis Inc | SLE | 05/25 | 12/25 | | |
NCT04895696: A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 2 | 268 | Europe, Japan, US, RoW | Afimetoran, BMS-986256, Placebo | Bristol-Myers Squibb | Systemic Lupus Erythematosus | 03/26 | 04/29 | | |
| Recruiting | 2 | 80 | US | Memantine, Namenda, Placebo | Vanderbilt University Medical Center, Evergreen Therapeutics, Inc., The University of Texas Health Science Center, Houston, The Cleveland Clinic | Lupus Erythematosus, Systemic | 06/26 | 12/26 | | |
| Recruiting | 2 | 30 | US | Descartes-08 | Cartesian Therapeutics | Systemic Lupus Erythematosus (SLE) | 11/25 | 11/26 | | |
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 180 | Europe, US, RoW | GLPG3667, Placebo | Galapagos NV | Systemic Lupus Erythematosus | 12/25 | 04/26 | | |
NCT05879718: A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. |
|
|
| Recruiting | 2 | 48 | Europe, Canada, US, RoW | Placebo, PF-06823859 | Pfizer | Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous | 12/25 | 11/26 | | |
2022-001796-14: An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). |
|
|
| Not yet recruiting | 1/2 | 12 | Europe | YTB323, Dispersion for infusion | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Systemic Lupus ErythematosusLupus Nephritis, Systemic Lupus ErythematosusLupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 1/2 | 30 | Europe | MB-CART19.1, MB-CART19.1, Dispersion for infusion | Miltenyi Biomedicine GmbH, Miltenyi Biomedicine GmbH | Adult patients with refractory active systemic lupus erythematosus (SLE) with organ involvement, Lupus, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05278663: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants |
|
|
| Completed | 1/2 | 26 | Japan | E6742, Placebo | Eisai Co., Ltd. | Lupus Erythematosus, Systemic | 09/23 | 09/23 | | |
NCT04643067: Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE |
|
|
| Completed | 1/2 | 64 | US | KPG-818 low dose, KPG-818 mid dose, KPG-818 high dose, Placebo | Kangpu Biopharmaceuticals, Ltd. | SLE; Drug | 08/23 | 08/23 | | |
NCT05465707: A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1/2 | 40 | NA | CM313 2 mg/kg, CM313 4 mg/kg, CM313 8 mg/kg, CM313 16 mg/kg, Placebo | Keymed Biosciences Co.Ltd | Systemic Lupus Erythematosus | 10/23 | 10/23 | | |
NCT06182969: A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. |
|
|
| Not yet recruiting | 1/2 | 40 | RoW | APG-2575, Placebo | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | SLE | 04/26 | 12/26 | | |
NCT06153095: A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1/2 | 30 | US, RoW | IMPT-514 | ImmPACT Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 02/27 | 02/27 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 24 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 03/25 | 03/25 | | |
| Not yet recruiting | 1/2 | 29 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH | SLE - Systemic Lupus Erythematosus | 03/25 | 03/27 | | |
NCT06106893: A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 15 | RoW | CD19 Universal CAR-γδ T Cells | Wuhan Union Hospital, China, Guangzhou Bio-gene Technology Co., Ltd | Systemic Lupus Erythematosus | 12/24 | 12/26 | | |
NCT06106906: A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 15 | RoW | CD19 CAR-T cell infusion | Wuhan Union Hospital, China, Guangzhou Bio-gene Technology Co., Ltd | Systemic Lupus Erythematosus | 12/24 | 12/26 | | |
NCT05798117: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 24 | Europe, US, RoW | YTB323 | Novartis Pharmaceuticals | Systemic Lupus Erythematosus, Lupus Nephritis | 10/26 | 10/26 | | |
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 12 | US | CABA-201 | Cabaletta Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 12/27 | 12/27 | | |
NCT06015230: Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE |
|
|
| Recruiting | 1/2 | 136 | RoW | low dose GR1603 in phase Ⅰb, high dose GR1603 in phaseⅠb, low dose GR1603 in phase Ⅱ, high dose GR1603 in phase Ⅱ, Placebo in phase Ⅱ | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Lupus Erythematosus, Systemic | 06/28 | 10/28 | | |